Laboratory Management Policies
Medical Mutual is working with Avalon Healthcare Solutions to implement a new Laboratory Management Program, which will go into effect on July 1, 2024.
The Laboratory Management Program includes new and revised laboratory policies and guidelines that will impact certain laboratory services, tests and procedures. These policies are based on the latest science for clinically accepted, peer-reviewed guidelines for lab services, and are available in the links below.
A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
A
B
B-Hemolytic Streptococcus Testing - G2159
Biomarker Testing for Autoimmune Rheumatic Disease - G2022
Biomarkers for Myocardial Infarction and Chronic Heart Failure - G2150
Biochemical Markers Of Alzheimer Disease and Dementia - G2048
Bone Turnover Markers Testing - G2051
C
Cardiovascular Disease Risk Assessment - G2050
Celiac Disease Testing - G2043
Cervical Cancer Screening - G2002
Coronavirus Testing in the Outpatient Setting - G2174
D
Diabetes Mellitus Testing - G2006
Diagnosis of Idiopathic Environmental Intolerance - G2056
Diagnosis of Vaginitis - M2057
Diagnostic Testing Of Common Sexually Transmitted Infections - G2157
Diagnostic Testing of Influenza - G2119
Diagnostic Testing of Iron Homeostasis & Metabolism - G2011
E
Epithelial Cell Cytology In Breast Cancer Risk Assessment - G2059
Evaluation of Dry Eyes - G2138
F
Fecal Calprotectin Testing - G2061
G
Gamma-glutamyl Transferase - G2173
General Inflammation Testing - G2155
H
Helicobacter Pylori Testing - G2044
Human Immunodeficiency Virus (HIV) - M2116
I
Identification Of Microorganisms Using Nucleic Acid Probes - M2097
Immune Cell Function Assay - G2098
Immunopharmacologic Monitoring of Therapeutic Serum Antibodies - G2105
In Vitro Chemoresistance And Chemosensitivity Assays - G2100
Intracellular Micronutrient Analysis - G2099
L
Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease - G2121
M
Measurement Of Thromboxane Metabolites For ASA Resistance - G2107
Metabolite Markers For Thiopurines Testing - G2115
N
O
Oral Cancer Screening and Testing - G2113
P
Pancreatic Enzyme Testing for Acute Pancreatitis - G2153
Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing - G2164
Pathogen Panel Testing - G2149
Pediatric Preventive Screening - G2042
Prenatal Screening (Nongenetic) - G2035
Prescription Medication and Illicit Drug Testing in the Outpatient Setting - T2015
Prostate Biopsy Specimen Analysis - G2007
Prostate Specific Antigen (PSA) Testing - G2008
S
Salivary Hormone Testing - G2120
Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases - G2123
Serum Testing for Evidence of Mild Traumatic Brain Injury - G2151
Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease - G2110
Serum Tumor Markers for Malignancies - G2124.
T
Testing For Alpha-1 Antitrypsin Deficiency - M2068
Testing for Diagnosis of Active or Latent Tuberculosis - G2063
Testing for Vector-Borne Infections - G2158
Thyroid Disease Testing - G2045
U
Urinary Tumor Markers For Bladder Cancer - G2125
Urine Culture Testing for Bacteria - G2156
V
Venous and Arterial Thrombosis Risk Testing - M2041
Vitamin B12 and Methylmalonic Acid Testing - G2014
Medical Mutual Laboratory Management Program Policies Disclaimer
Medical Mutual has collaborated with Avalon Healthcare Solutions (Avalon) on a Laboratory Management Program. The Laboratory Management Program includes certain Laboratory Services Policies (the “Laboratory Policies”) that offer guidance for payment determinations for a laboratory service or guidance for the way a laboratory service should be billed to Medical Mutual. The provider is responsible for submission of accurate claims.
The Laboratory Policies have been developed to assist in administering proper payment under benefit plans. Benefit plans vary in coverage and some plans may not provide coverage for some services discussed in these Laboratory Policies. Benefit determinations, coverage decisions, and payment determinations are subject to all terms and conditions of the applicable benefit plan, including definitions, specifically stated benefits, exclusions and benefit limitations, applicable state or federal laws, and other Laboratory Policies, Medical Mutual Corporate Reimbursement Policies, and Medical Mutual Corporate Medical Policies. Laboratory Policies are not intended to address every issue related to reimbursement of health care services, and Medical Mutual may use reasonable discretion in interpreting and applying Laboratory Policies to particular cases.
Laboratory Policies are considered guidelines and are not intended to infer or eliminate benefits or coverage for a specific member. Payment determinations are based on the specific facts regarding the service provided and how that service is billed.
Laboratory Policies do not constitute medical advice or medical care. The healthcare provider treating the member is solely responsible for the medical advice and treatment rendered to the member. Only the treating provider can deliver medical care and be responsible for the quality or appropriateness of the medical care and the skill with which it is provided.
Medical Mutual coverage decisions are benefit decisions only. Medical Mutual is not responsible for, does not provide and does not represent itself as a provider of medical care. If a service or supply is not eligible for benefits as determined by Medical Mutual, a member and the treating provider may proceed with that service or supply; however, benefits will not be available under the member’s plan.
Laboratory Policies are regularly reviewed, updated, withdrawn or added and therefore, subject to change. Payment determinations are made in the context of Laboratory Policies and other Medical Mutual policies, including Corporate Reimbursement Policies and Corporate Medical Policies, existing at the time the determination is made and are not subject to later revision as a result of a change in Laboratory Policy.